Immunitybio Net Margin
The Net Profit Margin of Immunitybio (IBRX) as of Sep 5, 2026 is -310.18 %. In the previous year, Net Profit Margin was -2,804.77 % — a change of -88.94% (higher).
Get this data via API
Financial Data API
Net Margin
-310.18 %
YoY
-88.94%
Last updated:
Net Profit Margin of Immunitybio is 2026 -310.18 % . Net Profit Margin of Immunitybio was 2025 -2,804.77 % . It decreases by -88.94% higher compared to the previous year.
For Immunitybio, the net margin of -310.2% is up versus -37,129.6% a few years ago.
The Immunitybio Net Margin history
3 Years
10 Years
25 Years
Max
Net Margin
Date
Net Margin
Jan 1, 2018
-204,736.17 USD
Jan 1, 2019
-152,997.67 USD
Jan 1, 2020
-36,669.59 USD
Jan 1, 2021
-37,129.55 USD
Jan 1, 2022
-173,569.58 USD
Jan 1, 2023
-93,761.41 USD
Jan 1, 2024
-2,804.77 USD
Jan 1, 2025
-310.18 USD
| YEAR | Net Margin | YoY |
|---|---|---|
| -310.18 % | -88.94% | |
| -2,804.77 % | -97.01% | |
| -93,761.41 % | -45.98% | |
| -173,569.58 % | +367.47% | |
| -37,129.55 % | +1.25% | |
| -36,669.59 % | -76.03% | |
| -152,997.67 % | -25.27% | |
| -204,736.17 % | -4.45% | |
| -214,273.33 % | -21.96% | |
| -274,565.91 % | +173.55% | |
| -100,371.19 % | +10,255.37% | |
| -969.27 % | +28,310.36% | |
| -3.41 % | — |
Access this data via the Eulerpool API
Immunitybio Stock analysis
What does Immunitybio do? Translate this as near as possible to English.
ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong.
The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics.
In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology.
ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies.
Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment.
The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study.
Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Immunitybio stock
Net Profit Margin of Immunitybio is -310.18 % in 2026.
Net Profit Margin of Immunitybio changed from -2,804.77 % to -310.18 %, representing a -88.94% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Net Profit Margin Immunitybio since 2006 – with annual values, charts, and detailed analysis.
Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Immunitybio with sector peers and the industry average to assess whether it is attractive.
To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.
Access this data via the Eulerpool API
Margins — Immunitybio
All Key Metrics — Immunitybio
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth